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Abstract 
Background: The shift towards an earlier diagnosis of breast cancer (BC) highlights the need for biomarkers that 
would identify patients at risk for relapse and metastatic spread and indicate the potential value of additional treat‑
ment strategies. Osteopontin (OPN) is a matricellular protein that has been suggested to be a potential biomarker in 
BC. In the present study, we used archived BC patient samples to assess the clinical utility of OPN.
Methods:  Formalin‑fixed paraffin‑embedded tumor tissue samples from 975 patients were collected from two 
large phase III randomized adjuvant chemotherapy trials (HE10/97 and HE10/00) that included patients with high risk 
BC. All tissue samples were assessed for ER, PgR, Ki67 and HER2 protein expression. OPN protein and mRNA expres‑
sion was evaluated using immunohistochemistry and quantitative reverse transcription‑polymerase chain reaction, 
respectively.
Results: OPN mRNA expression data were available for 814 patients, whereas OPN protein expression data were 
available for 546 patients. The majority of patients were ER/PgR‑positive (78.3%), HER2‑negative (76.5%) and Ki67‑pos‑
itive (55.2%) and had received adjuvant radiation therapy (76.8%) and hormonal therapy (81.1%). OPN mRNA expres‑
sion was significantly associated with age (60.9% in high OPN tumors vs. 54.1% in low OPN tumors, p = 0.047), ER/
PgR‑negative status (25.7 vs. 17.2%, p = 0.004) and BC subtypes (p = 0.021). In addition, high OPN mRNA expression 
was significantly associated with reduced DFS (HR 1.26, 95% CI 1.00–1.59, Wald’s p = 0.050) and OS (HR 1.37, 95% CI 
1.05–1.78, p = 0.019), while it retained its prognostic significance for both DFS (HR 1.39, 95% CI 1.10–1.77, p = 0.007) 
and OS (HR 1.54, 95% CI 1.61–2.05, p = 0.003) in the multivariate analysis.
Conclusions: We showed that high OPN mRNA expression is associated with decreased DFS and OS in a large cohort 
of BC patients treated with adjuvant chemotherapy in a clinical trial setting. Our results suggest that OPN may serve as 
a prognostic factor and a potential target for therapy.
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Background
The process of metastasis is responsible for the death 
of most patients with primary breast cancer. In clinical 
practice, to identify those patients at high risk of dying 
from metastatic spread, a series of prognostic pathologic 
factors are used. In addition, evaluation of biomarkers 
that may potentially play a role in tumor pathology allows 
physicians to prospectively select breast cancer patients 
for specific therapies. Currently, we use three predictive 
companion diagnostic tests for treatment selection: estro-
gen receptors (ER) and progesterone receptors (PgR) for 
endocrine therapy and human epidermal growth factor 
receptor 2 (HER2/neu) for anti-HER2 therapies. Despite 
the use of these three biomarkers for personalized risk 
stratification, a substantial proportion of patients still die 
of the disease. Therefore, we must identify additional bio-
markers in order to improve the prognosis of breast can-
cer patients.
In addition to genetically altered cancer cells, a tumor 
mass consists of various normal cells that actively con-
tribute to tumor progression, including the metastatic 
process. Tumor and stromal cells generate the extracel-
lular matrix (ECM), which comprises structural proteins 
and proteins that regulate cell function and their interac-
tions, such as osteopontin (OPN, SPP1) and other matri-
cellular proteins. Matricellular proteins are involved in 
several cellular processes including cell adhesion and 
migration, ECM deposition, cell proliferation and sur-
vival [1]. All these processes are also important for 
primary tumor growth and metastasis, in which matri-
cellular proteins are frequently aberrantly expressed. 
In addition, in a recent study using SPP1−/− mice along 
with gene silencing in tumor cells, OPN produced by 
tumor cells supported their survival in the blood stream, 
whereas both tumor- and host-derived OPN, particularly 
from myeloid cells, rendered the metastatic site more 
immunosuppressive [2].
Although OPN is not tumor-specific, its potential as 
a tumor biomarker has been demonstrated in several 
malignancies, including breast cancer [3, 4]. Elevated 
OPN expression has been associated with poor survival 
of cancer patients with different tumor histotypes [5–8]. 
Moreover, high OPN plasma concentrations were found 
in patients with metastatic breast cancer compared to 
healthy volunteers [9], while a number of studies have 
demonstrated that OPN may be associated with breast 
cancer progression and metastasis [10–12]. However, 
emerging data regarding the ability of OPN to predict 
overall survival (OS) and disease-free survival (DFS) in 
breast cancer patients have been inconsistent [13–15]. In 
the present study, we seek to determine the clinical utility 
of osteopontin in early breast cancer. To accomplish our 
goal we used archived samples from two large phase III 
randomized adjuvant trials in breast cancer patients.
Methods
Patient population
This was a retrospective translational research study 
among 1681 high-risk early breast cancer patients, 
enrolled in two prospective phase III trials. The 
HE10/97 trial [16] was a randomized phase III trial 
(ACTRN12611000506998) in patients with intermediate/
high-risk operable breast cancer, comparing four cycles of 
epirubicin (E) followed by four cycles of intensified CMF 
(E-CMF) with three cycles of E, followed by three cycles 
of paclitaxel (T, Taxol®, Bristol Myers-Squibb, Princeton, 
NJ) followed by three cycles of intensified CMF (E-T-
CMF). The current definition of high-risk breast cancer is 
based on the “International expert consensus on the pri-
mary therapy of early breast cancer 2007” [17]. Specifi-
cally, high-risk patients were node-positive patients with 
1–3 involved lymph nodes and ER and PgR absent, or 
HER2/neu gene overexpressed or amplified; or node-pos-
itive patients with 4 or more involved lymph nodes. The 
cycles were given every two weeks with G-CSF support. 
Dose intensity of all drugs in both treatment arms was 
identical, but cumulative doses and duration of chemo-
therapy period differed. In total, 595 eligible patients 
entered the study in a period of 3.5 years (1997–2000).
The HE10/00 trial [18, 19] was a randomized phase III 
trial (ACTRN12609001036202), in which patients were 
treated with E-T-CMF (exactly as in the HE10/97 trial) or 
with four cycles of epirubicin/paclitaxel (ET) combina-
tion (given on the same day) every three weeks followed 
by three cycles of intensified CMF every two weeks (ET-
CMF). By study design, the cumulative doses and the 
chemotherapy duration were identical in the two arms 
but dose intensity of epirubicin and paclitaxel was dou-
ble in the E-T-CMF arm. A total of 1086 eligible patients 
with node-positive operable breast cancer were accrued 
in a period of 5 years (2000–2005).
HER2-positive patients received trastuzumab upon 
relapse, as previously described [20]. Treatment sched-
ules for the two studies are shown in Additional file  1: 
Trial registration Australian New Zealand Clinical Trials Registry; HE10/97 ACTRN12611000506998; HE10/00 
ACTRN12609001036202
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Table S1. Baseline characteristics and clinical outcomes 
of both trials have already been described [16, 18, 19, 21]. 
Primary tumor diameter, axillary nodal status and tumor 
grade were obtained from the pathology report. Clini-
cal protocols were approved by local regulatory authori-
ties, while the present translational research study was 
approved by the “Papageorgiou” Hospital Institutional 
Review Board (July 15, 2013) and the Bioethics Com-
mittee of the Aristotle University of Thessaloniki School 
of Medicine (December 18, 2013). All patients signed a 
study-specific written informed consent before randomi-
zation, which in addition to giving consent for the trial 
allowed the use of biological material for future research 
purposes. All clinical investigations related to the present 
study have been conducted according to the principles 
expressed in the Declaration of Helsinki.
Tissue microarray (TMA) construction
Formalin-fixed paraffin-embedded (FFPE) tumor tissue 
samples from 975 patients (58.0% of 1681 randomized 
patients) were collected from both trials, retrospectively 
in the first (HE10/97) and prospectively in the second 
(HE10/00). The REMARK diagram [22] for the study 
is shown in Fig.  1. Hematoxylin-eosin stained sections 
from the tissue blocks were reviewed by two experienced 
breast cancer pathologists and the most representative 
tumor areas were marked for the construction of the 
ΤΜΑ blocks with the use of a manual arrayer (Model 
I, Beecher Instruments, San Prairie, WI), as previously 
described [23, 24]. Each case was represented by 2 tis-
sue cores, 1.5  mm in diameter, obtained from the most 
representative areas of primary invasive tumors or in 
some cases (9.6%) from synchronous axillary lymph node 
metastases and re-embedded in 51 microarray blocks. 
Each TMA block contained 38–66 tissue cores from the 
original tumor tissue blocks, while cores from various 
neoplastic, non-neoplastic and reactive tissues were also 
included, serving as orientation controls for slide-based 
assays. Cases not represented, damaged or inadequate on 
the TMA sections were re-cut from the original blocks, 
when material was available, and these sections were 
used for protein expression analysis.
Immunohistochemistry (IHC)
Immunohistochemical labeling was performed according 
to standard protocols on serial 2.5 μm thick sections from 
the original blocks or the TMA blocks. To assure opti-
mal reactivity, immunostaining was applied 7–10  days 
after sectioning at the Laboratory of Molecular Oncol-
ogy of the Hellenic Foundation for Cancer Research, 
Aristotle University of Thessaloniki School of Medicine. 
The staining procedures for HER2 (A0485 polyclonal 
antibody, Dako, Glostrup, Denmark), estrogen receptor 
(ER, clone 6F11, Novocastra™, Leica Biosystems, New-
castle, U.K), progesterone receptor (PgR, clone 1A6, 
Novocastra™, Leica Biosystems) and Ki67 (clone MIB-1, 
Dako) were performed using a Bond Max™ autostainer 
(Leica Microsystems, Wetzlar, Germany), as previously 
described in detail [25–28]. The staining procedures 
for OPN (clone OP3  N, code NCL-O-PONTIN, Novo-
castra™, Leica Biosystems) were also performed using a 
Bond Max™ autostainer, as previously described [29].
Interpretation of the IHC results
The evaluation of all IHC sections was done by two 
experienced breast cancer pathologists, blinded as to 
the patients’ clinical characteristics and survival data, 
according to existing established criteria, as previously 
described [20]. Briefly, HER2 protein expression was 
scored in a scale from 0 to 3+, the latter corresponding 
to uniform, intense membrane staining in >30% inva-
sive tumor cells [30]; ER and PgR were evaluated using 
the Histoscore method (max score: 400) and were con-
sidered positive if staining was present in ≥1% of tumor 
cell nuclei [31]; for Ki67, the expression was defined as 
low (<20%) or high (≥20%) based on the percentage of 
stained/unstained nuclei from the tumor areas [32]; and, 
OPN protein expression was scored in a scale from 0 to 
8, using the Allred scoring system, with scores 5–8 being 
considered to be high expression [14, 33]. If one of the 
tissue cores was lost or damaged the overall score was 
determined from the remaining one. When whole tissue 
sections were used, the entire tumor area was evaluated. 
Of the 975 FFPE tumor tissue samples collected, only 550 Fig. 1 Remark diagram
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(56.4%) had enough material left, in the TMAs and/or the 
original blocks, for the evaluation of OPN protein expres-
sion needed for the present study.
Fluorescence in situ hybridization (FISH)
TMA sections or whole tissue sections (5  μm thick) 
were used for FISH analysis, using the ZytoLight® SPEC 
HER2/TOP2A/CEP17 triple color probe (ZytoVision, 
Bremerhaven, Germany), as previously described [34]. 
FISH was performed according to the manufacturer’s 
protocol with minor modifications in all cases, not 
only the HER2 IHC 2+ cases. Four carcinoma cell lines 
(MDA-MB-231, MDA-MB-175, MDA-MB-453 and 
SK-BR-3) from the Oracle HER2 Control Slide (Leica 
Biosystems), with a known HER2 gene status, were also 
used as a control for the FISH assays and analyzed for 
HER2 genomic status.
For all probes, sequential (5 planes at 1.0  μm) digital 
images were captured using the Plan Apo VC 100×/1.40 
oil objective (Nikon, Japan) using specific filters for each 
probe. The resulting images were reconstructed using 
specifically developed software for cytogenetics (XCyto-
Gen, ALPHELYS, Plaisir, France). Processed sections 
were considered eligible for FISH evaluation according 
to the ASCO/CAP criteria [30]. For the evaluation of the 
HER2 gene status, non-overlapping nuclei from the inva-
sive part of the tumor were randomly selected, accord-
ing to morphological criteria using DAPI staining, and 
scored. The virtual slides of HER2, ER or PgR stains, cre-
ated as previously described [25], were used for select-
ing the invasive part of the tumor in each TMA. Twenty 
tumor nuclei were counted according to Press et al. [35]. 
The HER2 gene was considered to be amplified when the 
HER2/CEP17 ratio was >2.2 [30], or the mean HER2 copy 
number was >6 [36]. In cases with values at or near the 
cut-off (1.8–2.2), 20–40 additional nuclei were counted 
and the ratio was recalculated. In cases with a borderline 
ratio, additional FISH assays were performed in whole 
sections [37]. The data from the evaluation of TOP2A 
gene status were neither analyzed nor presented in the 
present manuscript. All primary image data of the TMA 
and whole tumor sections have been digitally scanned and 
made publicly available at: https://figshare.com/articles/
Photos_of_TMA_and_whole_tumor_sections/3485879
RNA isolation and quantitative reverse 
transcription‑polymerase chain reaction (qRT‑PCR) 
assessment
Prior to RNA isolation, macrodissection of tumor areas 
was performed in most (69%) of the FFPE sections (all 
sections with <50% tumor cell content). More than 
one FFPE section (2–8 sections, 10  μm thick) was used 
for RNA extraction when the tumor surface of a given 
sample was less than 0.25 cm2. From each FFPE section 
or macrodissected tissue fragments, RNA was extracted 
using a standardized fully automated isolation method 
for total RNA from FFPE tissue, based on germanium-
coated magnetic beads (XTRAKT kit, STRATIFYER 
Molecular Pathology GmbH, Cologne, Germany) in 
combination with a liquid handling robot (XTRAKT 
XL, STRATIFYER Molecular Pathology GmbH), as pre-
viously described in detail [26, 28, 38, 39]. The method 
involves extraction-integrated deparaffinization and 
DNase I digestion steps. The quality and quantity of RNA 
was checked by measuring CALM2 expression as a sur-
rogate for amplifiable mRNA by qRT-PCR. CALM2 was 
used as endogenous reference, since it had previously 
been identified as being highly and stably expressed 
among breast cancer tissue samples. Of the 975 FFPE 
tumor tissue samples collected, 819 (84.0%) had enough 
material left for RNA isolation needed for the present 
study.
qRT-PCR primers and labeled hydrolysis probes were 
selected using Primer Express® Software, Version 2.2 
and 3 (Applied Biosystems/Life Technologies, Karlsruhe, 
Germany), according to the manufacturer’s instructions, 
and were controlled for single nucleotide polymor-
phisms. All primers, probes and amplicons were checked 
for their specificity against nucleotide databases at NCBI 
using Basic Local Alignment Search Tool (BLAST). 
Primers and probes were purchased from Eurogentec 
S.A. (Seraing, Belgium). For each primer/probe set, the 
amplification efficiency was tested, aiming to reach com-
parable efficiency of >90% (efficiency range from 97.7 to 
99.7%). Primers and hydrolysis probes were diluted to 
100 µM, using a stock solution with nuclease-free water 
(Life Technologies GmbH, Darmstadt, Germany) [28, 
39]. qRT-PCR was applied for the relative quantification 
(RQ) of OPN. The Primer/Probe (YakimaYellow/FAM-
labeled) sets used for amplification of the target and ref-
erence genes were the following (5′ → 3′):
OPN probe CGACCAAGGAAAACT
Forward primer CAGCCTTCTCAGCCAAACG





For PCR, 0.5 µM of each primer and 0.25 µM of each 
probe were used. All quantitative reverse-transcription 
PCRs were performed in triplicates using the Super-
Script® III Platinum® One-Step qRT-PCR kit (Invitrogen/
Page 5 of 11Psyrri et al. J Transl Med  (2017) 15:30 
Life Technologies, Darmstadt, Germany) according to the 
manufacturer’s instructions. Experiments were performed 
on a Stratagene Mx3005p (Agilent Technologies, Wald-
bronn, Germany) with 30 min at 50 °C and 2 min at 95 °C 
followed by 40 cycles of 15 s at 95  °C and 30 s at 60  °C. 
The lengths of the amplicons detected by the OPN and 
CALM2 assays were 64 and 72 bp, respectively, with PCR 
efficiencies [E = 1(10-slope)] of 97.7 and 99.7%, respectively. 
Samples were considered eligible for further investigation 
(N = 814, Fig. 1) when the cycle threshold (CT) values of 
the housekeeping gene were ≤33.5 (triplicate mean val-
ues). Relative expression levels (relative quantification, 
RQ) of the target transcripts were calculated as 40-DCT 
values (DCT = mean CT target gene − mean CT house-
keeping gene) to yield positively correlated numbers and 
to facilitate comparisons [28, 39]. A commercially avail-
able human reference RNA (Stratagene qPCR Human 
Reference Total RNA, Agilent Technologies, Waldbronn, 
Germany) was used as positive control. No-template con-
trols were assessed in parallel to exclude contamination.
Statistical analysis
DFS was defined as time from study entry to first tumor 
recurrence, secondary neoplasm, or death from any cause 
[40]. OS was measured from study entry until death from 
any cause. Surviving patients were censored at the date of 
last contact.
The prognostic value of OPN mRNA expression was 
examined in terms of DFS and OS, using the 50th percen-
tile (median value) as the optimal cut-off and if this is not 
significant the upper and lower quartiles of the mRNA 
distribution were to be examined, as possible thresholds. 
In case a cut-off was of prognostic significance, it was 
used to dichotomize tumor expression into low and high. 
OPN protein expression was dichotomized into high ver-
sus low using the Allred 8-unit IHC scoring system (0–4: 
low vs. 5–8: high) [14]. The Fisher’s exact test or Pearson 
Chi square were used for group comparison of categori-
cal data, while for continuous data the Mann–Whitney 
test was used. Kaplan–Meier curves and log-rank tests 
were used for comparing time to event distributions.
Univariate Cox proportional hazard regression analy-
ses were performed for OPN mRNA and protein expres-
sion. Predictive significance of OPN mRNA and protein 
expression was examined by interaction tests between 
OPN mRNA or protein expression and chemotherapy 
treatment with paclitaxel (yes vs. no), hormonal therapy 
(yes vs. no) and radiation therapy (yes vs. no) using Cox 
regression models. In multivariate analysis, a backward 
selection procedure with a removal criterion p  >  0.15 
based on the likelihood ratio test was performed to iden-
tify significant clinicopathological variables among the 
following: age (≥50 vs. <50), nodal status (≥4 vs. 1–3 
positive lymph nodes), tumor size (2–5 vs. ≤2  cm and 
>5  vs. ≤2  cm), radiation therapy (yes vs. no), hormonal 
therapy (yes vs. no), ER/PgR status (positive vs. nega-
tive), type of operation (modified radical mastectomy 
vs. breast-conserving surgery), chemotherapy treatment 
(E-T-CMF vs. E-CMF, ET-CMF vs. E-CMF) and OPN 
mRNA (high vs. low) or protein expression (high vs. low).
Results of this study were presented according to 
reporting recommendations for tumor marker prognos-
tic studies [22]. This study is prospective-retrospective as 
described in Simon et al. [41]. The SAS software was used 
for statistical analysis (SAS for Windows, version 9.3, 
SAS Institute Inc., Cary, NC).
Results
Patient characteristics
OPN mRNA expression data were available for 814 
patients, whereas OPN protein expression data were 
available for 546 patients. Basic clinical and pathologi-
cal characteristics of patients are presented in Table  1. 
The majority of patients (centrally assessed by IHC and 
FISH in the case of HER2) were ER/PgR-positive (78.3%), 
HER2-negative (76.5%) and Ki67-positive (55.2%) and 
had received adjuvant radiation therapy (76.8%) and hor-
monal therapy (81.1%). High OPN mRNA expression was 
noted in 50% of the patients, while 89.2% of the patients 
had high OPN protein expression (Allred score 5–8).
Normalized OPN mRNA expression
The distribution of tumor samples according to the nor-
malized expression of mRNA encoding for OPN is shown 
in Fig.  2. The median value for OPN mRNA expression 
was 40.2, with a range of 33.5–44.7. The 50th percentile 
(median value) was found to be the optimal cut-off for 
OPN mRNA expression in terms of both DFS and OS.
Association of OPN mRNA expression 
with clinicopathologic parameters
OPN mRNA expression was significantly associated with 
age, as patients older than 50 years demonstrated higher 
OPN mRNA expression compared to patients younger 
than 50 years (Chi square, p = 0.047). In addition, post-
menopausal and ER/PgR-negative patients were more 
frequent in the high OPN mRNA expressing group than 
in the low-expressing group (57.7 vs. 50.6%, Chi square, 
p  =  0.041 and 25.7 vs. 17.2%, p  =  0.004, respectively). 
Finally, there was a significant association between OPN 
mRNA expression and breast cancer subtypes (Chi 
square, p =  0.021), especially in triple-negative patients 
(14.5% in the high OPN mRNA expressing group vs. 8.0% 
in the low expressing group). There were no other signifi-
cant associations between OPN mRNA expression and 
selected clinicopathological parameters (Table 2).
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Prognostic/predictive value of OPN mRNA and OPN 
protein expression
Survival status of all patients was updated in June 2014. 
The median follow-up time was 119.9  months (range 
0.1–191.9). During this time, 291 patients (35.5%) had 
developed documented disease progression and 226 
(27.6%) had died.
Univariate Cox regression analysis showed that high 
OPN mRNA expression (above the 50th percentile) was 
associated with increased risk for relapse (HR 1.26, 95% 
CI 1.00–1.59, Wald’s p = 0.050) and death (HR 1.37, 95% 
CI 1.05–1.78, p = 0.019). Kaplan–Meier curves for DFS 
and OS according to OPN mRNA expression are shown 
in Fig. 3.
OPN mRNA expression was not predictive for benefit 
from the addition of paclitaxel to the E-CMF regimen 
either for DFS (interaction p = 0.97) or OS (interaction 
p =  0.88). In addition, OPN mRNA expression was not 
predictive for benefit either from hormonal therapy (DFS 
interaction p = 0.76 and OS p = 0.57) or from radiation 
therapy (DFS interaction p = 0.73 and OS p = 0.67).




 <50 348 (42.5)
 ≥50 471 (57.5)
NPI score
 Median (range) 5.52 (3.0–9.0)
Treatment group
 E‑CMF 123 (15.0)
 E‑T‑CMF 392 (47.9)
 ET‑CMF 304 (37.1)
Menopausal status
 Premenopausal 375 (45.8)
 Postmenopausal 444 (54.2)
Breast surgery
 Modified radical mastectomy 579 (70.7)
 Breast‑conserving surgery 240 (29.3)
ER/PgR status
 Negative 165 (21.7)
 Positive 596 (78.3)
Histological grade
 I–II 406 (49.6)
 III–Undifferentiated 413 (50.4)
Tumor size (cm)
 ≤2 181 (22.8)
 2–5 517 (65.2)
 >5 95 (12.0)
Positive lymph nodes
 1–3 nodes 331 (40.5)
 ≥4 nodes 487 (59.5)
Adjuvant radiation therapy
 No 184 (23.2)
 Yes 609 (76.8)
Adjuvant hormonal therapy
 No 154 (18.9)
 Yes 661 (81.1)
Bone metastases
 No 711 (88.4)
 Yes 93 (11.6)
HER2 status
 Negative 593 (76.5)
 Positive 182 (23.5)
Ki67 protein expression
 Low (<20%) 367 (44.8)
 High (≥20%) 452 (55.2)
Subtypes
 Luminal A 245 (32.3)
 Luminal B 248 (32.8)
 Luminal‑HER2 99 (13.1)




 Triple‑negative 86 (11.4)
OPN mRNA expression
 Low (<50th percentile) 407 (50.0)
 High (≥50th percentile) 407 (50.0)
OPN protein expression
 Low (0–4 Allred score) 59 (10.8)
 High (5–8 Allred score) 487 (89.2)
Fig. 2 Distribution of OPN mRNA expression values. Median 40.2, 
range 33.5–44.7. Red line represents the 50th percentile (median)
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With regard to prognostic value, OPN protein expres-
sion was not significantly associated with either DFS (HR 
0.81, 95% CI 0.52–1.26, p = 0.35) or OS (HR 0.78, 95% CI 
0.47–1.27, p =  0.32). The predictive value of OPN pro-
tein expression for benefit from the addition of paclitaxel 
to the E-CMF regimen was not examined due to the fact 
that one subgroup (E-CMF/low OPN protein expres-
sion) contained only one patient. OPN protein expres-
sion was not predictive for benefit either from hormonal 
Table 2 Association of  OPN mRNA expression 
with selected patient and tumor characteristics
Low (N = 407) High (N = 407) p value
N (%) N (%)
Age (in years)
 <50 187 (45.9) 159 (39.1) 0.047
 ≥50 220 (54.1) 248 (60.9)
NPI score
 Median (range) 5.6 (3.0–7.8) 5.5 (3.2–9.0) 0.64
Treatment group
 E‑CMF 69 (17.0) 53 (13.0) 0.18
 E‑T‑CMF 196 (48.1) 192 (47.2)
 ET‑CMF 142 (34.9) 162 (39.8)
Menopausal status
 Premenopausal 201 (49.4) 172 (42.3) 0.041
 Postmenopausal 206 (50.6) 235 (57.7)
Type of operation
 Modified radical mastec‑
tomy
285 (70.0) 290 (71.3) 0.70
 Breast conserving surgery 122 (30.0) 117 (28.7)
ER/PgR status
 Negative 65 (17.2) 98 (25.7) 0.004
 Positive 312 (82.8) 283 (74.3)
Histological grade
 I–II 211 (51.8) 194 (47.7) 0.23
 III 196 (48.2) 213 (52.3)
Tumor size (cm)
 ≤2 122 (30.0) 126 (31.0) 0.85
 2–5 235 (57.7) 236 (58.0)
 >5 50 (12.3) 45 (11.0)
Positive lymph nodes
 1–3 nodes 154 (37.9) 175 (43.0) 0.14
 ≥4 nodes 252 (62.1) 232 (57.0)
Adjuvant RT
 No 80 (20.6) 103 (25.8) 0.081
 Yes 309 (79.4) 296 (74.2)
Adjuvant HT
 No 70 (17.3) 84 (20.7) 0.21
 Yes 335 (82.7) 321 (79.3)
Bone metastases
 No 363 (90.5) 346 (86.7)
 Yes 38 (9.5) 53 (13.3) 0.090
HER2 statusa
 Negative 290 (75.5) 300 (77.5) 0.51
 Positive 94 (24.5) 87 (22.5)
Ki67 protein expression
 Low (<20%) 186 (45.7) 179 (44.0)
 High (≥20%) 221 (54.3) 228 (56.0) 0.62
Subtypes
 Luminal A 125 (33.3) 120 (31.8) 0.021
 Luminal B 128 (34.0) 119 (31.5)
 Luminal‑HER2 58 (15.4) 41 (10.8)
Comparisons were made using Chi square or Fisher’s exact tests
RT radiation therapy, HT hormonal therapy
Significant p values are shown in italics
a Positive HER2 status: HER2 3+ by IHC or HER2 amplification by FISH
Table 2 continued
Low (N = 407) High (N = 407) p value
N (%) N (%)
 HER2‑enriched 35 (9.3) 43 (11.4)
 Triple‑negative 30 (8.0) 55 (14.5)
Fig. 3 Disease‑free survival (DFS) and overall survival (OS) according 
to OPN mRNA expression
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therapy (DFS interaction p =  0.27 and OS p =  0.95) or 
from radiation therapy (DFS interaction p = 0.97 and OS 
p = 0.97).
Multivariate analysis
In the multivariate Cox regression analysis, shown in 
Table 3, OPN mRNA expression retained its prognostic 
significance for both DFS (HR 1.34, 95% CI 1.04–1.71, 
Wald’s p =  0.022) and OS (HR 1.54, 95% CI 1.16–2.05, 
p  =  0.003). Four or more positive nodes and greater 
tumor size were found to be associated with higher risk 
for relapse and death, while adjuvant hormonal therapy 
was a favorable prognostic factor for both DFS and OS.
Discussion
In the present study, we sought to determine the prog-
nostic significance of OPN mRNA and protein expression 
in archived samples from two large phase III randomized 
adjuvant trials in breast cancer patients. At the time our 
adjuvant studies were started, OPN as a potential tumor 
biomarker in breast cancer was categorized as “+” on the 
Tumor Marker Utility Grading System (TMUGS) pub-
lished by Hayes et  al. [4], defined as “sufficient data are 
available to demonstrate that the marker correlates with 
the biologic process and/or biologic endpoint related to 
the use and that the marker results might affect favora-
ble clinical outcome for that use”. However, the marker is 
still considered investigational and should not be used for 
standard clinical practice. We demonstrated that OPN 
mRNA expression inversely correlated with DFS and OS, 
while it retained its independent prognostic significance 
in multivariate analysis for increased risk for both relapse 
and death. OPN protein expression assessed by conven-
tional IHC did not show an association with relapse and 
death. Regarding predictive significance, OPN mRNA 
and protein expression were not found to be predictive 
for benefit from paclitaxel chemotherapy, hormonal ther-
apy or radiation therapy in our patients.
In our study, we found that OPN mRNA expression 
was inversely associated with DFS and OS. Our study is 
the first, to our knowledge, to examine the prognostic 
significance of OPN mRNA and protein expression in 
breast cancer samples derived from patients treated in a 
clinical trial setting. A handful of studies have assessed 
the prognostic value of OPN in early breast cancer and 
our results are in agreement with these studies. Ortiz-
Martínez et  al. [42] analyzed by RT-PCR 309 breast 
cancer samples and 6 breast cancer cell lines for OPN 
mRNA expression, its splicing variant-c and OPN protein 
expression. The median fold change of total OPN mRNA 
expression was higher in HER2-positive and triple-neg-
ative/basal-like tumors, whereas OPN-c mRNA expres-
sion was upregulated in the triple-negative/basal-like 
subtype. We also found a significant association between 
OPN mRNA expression and breast cancer subtypes 
(p = 0.021), especially in triple-negative patients. In the 
study by Ortiz-Martinez et al. [42] DFS was significantly 
shorter for patients whose tumors overexpressed total 
OPN (67 vs. 73%) but in multivariate analysis only OPN-c 
mRNA expression emerged as a significant predictor for 
relapse. Moreover, increased OPN-c stratified subgroups 
of patients at higher risk of recurrence among immu-
nophenotypes, especially in the triple-negative/basal-like 
subtype (risk of relapse 70% in patients with low OPN-
expression vs. 83% in patients with OPN-c overexpres-
sion). Patani et  al. [43] analyzed 127 breast carcinomas 
and 33 normal tissues for OPN transcript levels using 
real-time PCR. OPN-a mRNA expression decreased with 
increasing TNM stage and was associated worse clinical 
outcome. OPN-b mRNA expression increased with his-
tological grade and Nottingham Prognostic Index (NPI) 
stage, was higher in patients who died of breast cancer 
than in those who were disease-free after 10  years and 
predicted DFS. OPN-c mRNA expression was associated 
with histological grade and poor prognosis. Furthermore, 
high expression levels predicted local recurrence, worse 
DFS and bone metastases [43].
Although OPN mRNA expression was associated with 
survival, OPN protein expression was not. The discord-
ant findings can be explained by several factors. Firstly, 
all mRNAs are not equally translated into proteins [44]. 
Table 3 Multivariate Cox regression analysis
HR hazard ratio, CI confidence interval
Disease‑free survival HR 95% CI p value
Number of positive nodes
 ≥4 versus 1–3 2.51 1.88–3.63 <0.001
Tumor size
 2–5 cm versus ≤2 cm 1.45 1.08–1.95 0.013
 >5 cm versus ≤2 cm 1.65 1.10–2.48 0.015
Adjuvant HT
 Yes versus no 0.69 0.51–0.93 0.016
OPN mRNA expression
 High versus low 1.34 1.04–1.71 0.022
Overall survival
Number of positive nodes
 ≥4 versus 1–3 3.59 2.48–5.19 <0.001
Tumor size
 2–5 cm versus ≤2 cm 1.59 1.13–2.34 0.009
 >5 cm versus ≤2 cm 1.87 1.18–2.97 0.008
Adjuvant HT
 Yes versus no 0.55 0.39–0.76 <0.001
OPN mRNA expression
 High versus low 1.54 1.16–2.05 0.003
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Secondly, microRNAs repress numerous genes by inhib-
iting mRNA translation into protein, while several post-
translational mechanisms control protein turnover and 
abundance [44]. Finally, it appears that there is a stronger 
evolutionary pressure for constant protein levels com-
pared to constant mRNA levels (reviewed in [44]). The 
above factors would also explain the lack of correla-
tion between OPN mRNA expression and OPN protein 
expression observed in our study.
Many studies have assessed the prognostic value 
of OPN protein expression in breast cancer and have 
yielded conflicting results [33, 45–50]. A recent meta-
analysis demonstrated that high OPN protein expression 
was positively associated with lymph node metastases 
(pooled odds ratio 2.03, 95% CI 1.20–3.43, p  =  0.008) 
and decreased OS (HR 3.69, 95% CI 1.45–9.42, p < 0.001, 
random-effects model) and DFS (pooled HR 2.40, 95% CI 
1.27–4.55, p  =  0.007, fixed-effects model) [51]. We did 
not however find a significant association of OPN protein 
status with either DFS or OS.
Our findings suggest a possible relationship between 
the ER signaling pathway and OPN mRNA expression. 
Coexpression of OPN and ERa has previously been 
reported in breast cancer patients [45, 48]. The asso-
ciation between OPN and two other estrogen inducible 
proteins, pS2 and PgR, was also significant in the above 
study by Rudland et  al. [48]. These associations suggest 
molecular connections between OPN and the ER signal-
ing pathway [52].
Our study has several strengths. There were strong 
laboratory and clinical data supporting our interest in 
exploring OPN as a biomarker in breast cancer. The 
patient population was well defined, since all patients 
included in the study were accrued in the context of 
two randomized adjuvant trials. All important patient 
and tumor characteristics were presented and were also 
included in the multivariate analyses. Both randomized 
trials had a long follow-up. Finally, to our knowledge, 
this is the largest study evaluating the prognostic impact 
of OPN mRNA and protein expression in early breast 
cancer.
A major limitation of our study is that this is a retro-
spective study; our results should therefore be confirmed 
in validation cohorts, applying the OPN mRNA cut-off 
used the present study. In addition, protein expression of 
OPN splice variants should also be evaluated by immu-
nohistochemistry, as suggested in a recent study by Zdu-
niak et al. [3].
Conclusions
In conclusion, we demonstrated that high OPN mRNA 
expression is associated with reduced DFS and OS in 
a large cohort of breast cancer patients treated with 
adjuvant chemotherapy in a randomized clinical trial 
setting. This finding has implications for the prognostic 
classification of patients, the use of dose-dense chemo-
therapy regimens in all patients with high OPN mRNA 
expression, as well as the use of novel more efficacious 
treatments when they become available in the future. 
In addition, our results suggest that OPN may serve as 
a potential molecular target for the treatment of breast 
cancer patients.
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